Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Ark Therapeutics Group plc

15 Feb 2013 10:39

ABERFORTH PARTNERS LLP - Form 8.3 - Ark Therapeutics Group plc

ABERFORTH PARTNERS LLP - Form 8.3 - Ark Therapeutics Group plc

PR Newswire

London, February 15

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A

PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

1. KEY INFORMATION

(a) Identity of the person whose positions/ Aberforth Partners LLP, ondealings are being disclosed:

behalf of discretionary clients.(b) Owner or controller of interests and shortpositions disclosed, if different from 1(a):The naming of nominee or vehicle companies isinsufficient

(c) Name of offeror/offeree in relation to Ark Therapeutics Group plcwhose relevant securities this form relates:

Use a separate form for each offeror/offeree(d) If an exempt fund manager connected withan offeror/offeree, state this and specifyidentity of offeror/offeree:(e) Date position held/dealing undertaken: 14 February 2013(f) Has the discloser previously disclosed, or Y/N NOare they today disclosing, under the Code in

respect of any other party to this offer? If YES, specify which:

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

(a) Interests and short positions in the relevant securities of the offeror orofferee to which the disclosure relates following the dealing (if any)

Class of relevant security: Ordinary Shares Interests Short positions Number % Number %(1) Relevant securities owned 24,580,092 11.75 0 0.0and/or controlled:(2) Derivatives (other thanoptions):(3) Options and agreements topurchase/sell:TOTAL: 24,580,092 11.75 0 0.0

All interests and all short positions should be disclosed.

Details of any open derivative or option positions, or agreements to purchaseor sell relevant securities, should be given on a Supplemental Form 8 (OpenPositions).

(b) Rights to subscribe for new securities (including directors' and otherexecutive options)

Class of relevant security in N/Arelation to which subscription rightexists:Details, including nature of the N/Arights concerned and relevantpercentages:

If there are positions or rights to subscribe to disclose in more than oneclass of relevant securities of the offeror or offeree named in 1(c), copytable 2(a) or (b) (as appropriate) for each additional class of relevantsecurity.

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

(a) Purchases and sales

Class of relevant Purchase/sale Number of Price per unit security securities Ordinary Shares Sale 1,930,000 1.025p

(b) Derivatives transactions (other than options)

Class of Product Nature of dealing Number of Price per relevant description reference unit security e.g. opening/closing a securities e.g. CFD long/short position, increasing/reducing a long/short position N/A

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Class of Product Writing, Number of Exercise Type Expiry Optionrelevant description purchasing, securities price

date moneysecurity e.g. call selling, to which per unit e.g. paid/ option varying option American, received etc. relates European per unit etc. N/A(ii) Exercising Class of relevant Product Number of Exercise price per security description securities unit e.g. call option N/A

(d) Other dealings (including subscribing for new securities)

Class of relevant Nature of dealing Details Price per unit

security (if applicable) e.g. subscription, conversion N/A

The currency of all prices and other monetary amounts should be stated.

Where there have been dealings in more than one class of relevant securities ofthe offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (asappropriate) for each additional class of relevant security dealt in.

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement orunderstanding, formal or informal, relating to relevant securities which maybe an inducement to deal or refrain from dealing entered into by the personmaking the disclosure and any party to the offer or any person acting inconcert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

None

(b) Agreements, arrangements or understandings relating to options orderivatives

Details of any agreement, arrangement or understanding, formal or informal,between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevantsecurities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None(c) AttachmentsIs a Supplemental Form 8 (Open Positions) attached? Y/N NODate of disclosure: 15 February 2013Contact name: David Holland, for Aberforth Partners LLPTelephone number: 0131 220 0733

Public disclosures under Rule 8 of the Code must be made to a RegulatoryInformation Service and must also be emailed to the Takeover Panel atmonitoring@disclosure.org.uk . The Panel's Market Surveillance Unit isavailable for consultation in relation to the Code's dealing disclosurerequirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .

Date   Source Headline
17th May 201010:17 amRNSForm 8.5 (EPT/NON-RI)
14th May 201011:16 amRNSForm 8.5 (EPT/RI)
14th May 20109:36 amRNSForm 8.5 (EPT/NON-RI)
12th May 201010:39 amRNSForm 8.5 (EPT/RI)
12th May 20109:49 amRNSForm 8.5 (EPT/NON-RI)
11th May 20108:41 amRNSForm 8.5 (EPT/NON-RI)
10th May 20104:19 pmRNSForm 8.3 - [Ark Therapeutics Grp]
10th May 201010:41 amRNSForm 8.5 (EPT/NON-RI)
7th May 20102:37 pmRNSForm 8.3 - Ark Therapeutics Grp
7th May 201010:03 amRNSForm 8.5 (EPT/RI)
7th May 201010:01 amRNSForm 8.5 (EPT/NON-RI)
6th May 201012:24 pmRNSForm 8.3 - Ark Therapeutics Group PLC
6th May 20109:49 amRNSForm 8.5 (EPT/NON-RI)
5th May 201011:48 amRNSForm 8.3 - (Ark Therapeutics)
5th May 20107:00 amRNSStrategic Review
4th May 20101:54 pmRNSForm 8 (OPD) Ark Therapeutics Group
4th May 20101:36 pmRNSForm 8.5 (EPT/NON-RI)
30th Apr 20101:43 pmRNSForm 8.3 - Ark Therapeutics Group PLC
30th Apr 201012:05 pmRNSTotal Voting Rights
30th Apr 201012:03 pmRNSDirector/PDMR Shareholding
30th Apr 201011:55 amRNSForm 8 (DD) - Ark Therapeutics Group PLC
30th Apr 201010:49 amRNSForm 8.5 (EPT/RI)
29th Apr 201011:11 amRNSForm 8.5 (EPT/NON-RI)
29th Apr 201011:04 amRNSForm 8.5 (EPT/NON-RI)
28th Apr 20102:44 pmRNSForm 8.3 - Ark Therapeutics Group plc
28th Apr 201010:31 amRNSForm 8.5 (EPT/NON-RI)
27th Apr 201011:40 amRNSForm 8.5 (EPT/RI)
26th Apr 20102:53 pmRNSForm 8.3 - ARK THERAPEUTICS
26th Apr 201012:43 pmRNSForm 8.3 - Ark Therapeutics Group plc
26th Apr 201011:30 amRNSForm 8.5 (EPT/RI)
26th Apr 20109:42 amRNSForm 8.5 (EPT/NON-RI)
23rd Apr 201011:43 amRNSForm 8.3 - ARK THERAPEUTICS
23rd Apr 201011:36 amRNSForm 8.5 (EPT/RI)
23rd Apr 201010:16 amRNSForm 8.5 (EPT/NON-RI)
22nd Apr 201011:33 amRNSForm 8.3 - ARK THERAPEUTICS
22nd Apr 201011:03 amRNSForm 8.3 - Ark Therapeutics Group Plc
22nd Apr 20109:48 amRNSForm 8.5 (EPT/RI)
21st Apr 20101:47 pmRNSForm 8.3 - ARK THERAPEUTICS
21st Apr 201012:05 pmRNSResult of AGM
21st Apr 20109:11 amRNSForm 8.5 (EPT/NON-RI)
20th Apr 20103:56 pmRNSForm 8.3 - Ark Therapeutics Group Plc
20th Apr 201012:49 pmBUSForm 8.3 - Ark Therapeutics Group plc
20th Apr 201011:37 amRNSForm 8.5 (EPT/RI)
20th Apr 20109:48 amRNSForm 8.3 - Ark Therapeutics Plc
20th Apr 20108:53 amRNSForm 8.5 (EPT/NON-RI)
19th Apr 20102:44 pmRNSForm 8.3 - Ark Therapeutics Group plc
19th Apr 201011:31 amRNSForm 8.5 (EPT/NON-RI)
19th Apr 20107:00 amRNSResearch Update
16th Apr 201010:32 amRNSEPT Disclosure
16th Apr 20109:32 amRNSEPT Disclosure

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.